Fig. 3: BUD31 promotes proliferation and xenograft tumor growth in ovarian cancer.

The EdU assay (a) and cell proliferation assay (b) were performed in ovarian cancer cells with BUD31 overexpression (HEYA8, A2780) or knockdown (HEYA8, OV90) compared to corresponding controls (n = 3 for the EdU and n = 5 biologically independent experiments for the cell proliferation assay). Cell proliferation was measured using the MTT cell proliferation assay. Absorbance at 570 nm at each time point was compared to the initial state (time = 1 day). c Luciferase signals of intraperitoneal injected nude mice and photon flux quantification. Nude mice were injected with luciferase-expressing HEYA8 cells with a dox-inducible BUD31 knockdown system (n = 6 per group). Administration of doxycycline (1.2 g/L) started one week after the cell implantation. The bounds of the box were the upper and lower quartile with the median value in the center. The whiskers indicated the minima and maxima. d IHC staining of BUD31 and Ki-67 expression in xenograft tumors of HEYA8 cells with BUD31 knockdown compared to corresponding controls. e TUNEL assay to quantify the apoptotic cells in xenograft tumors with BUD31 knockdown compared to corresponding controls. The p value was obtained by two-tailed unpaired (a–c), and the results are presented as the mean ± SD. *p < 0.05, **p < 0.01. Source data are provided as a Source Data file.